A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated with Tourette Syndrome
If your child (ages 6-16) have been diagnosed with Tourette syndrome you may be eligible to take part in a research study of an experimental drug called TEV-50717, which is being developed as a treatment for tics associated with Tourette syndrome in children and adolescents.
If your child (ages 6-16) is eligible and you choose for your child to take part in this study, your child will be randomly assigned to either the TEV-50717 study treatment group or the placebo (an inactive substance that looks identical to TEV-50717) study treatment group.
Your child will have one in three (or 33%) chance of receiving high-dose of TEV50717 (the "active drug"), one in three (or 33%) chance of receiving low-dose of TEV50717 and one in three (or 33%) chance of receiving placebo. Which study treatment your child receives is decided at random by a computer (purely by chance, like the tossing of a coin).
Visits, procedures and eligibility can be explained by the study team. Please contact Derek Ridgeway for more information:
Can be done from home
KeywordsTourette Syndrome, Neurology
Principal InvestigatorIrene Andonia C. Malaty, MD
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.